Jubilant Ingrevia Limited — Q1 FY27 earnings call

Call held 27 Jul 2026

Management summary

Jubilant Ingrevia Limited reported a strong Q1 FY27, achieving a 15-quarter high in revenue and significant year-on-year growth in EBITDA and PAT, driven by healthy volume growth and improved realizations across Specialty Chemicals, Nutrition & Health, and Chemical Intermediates segments. The company is progressing on its strategic initiatives, including new plant commissioning and pipeline expansion, despite some challenges related to a large CDMO contract's volume visibility and raw material price volatility.

Highlights

  • Revenue grew by 25% year-on-year to ₹1,300 crores, marking a 15-quarter high.

  • EBITDA increased by 36% year-on-year and 22% sequentially to ₹209 crores.

  • PAT grew by 41% year-on-year and 22% quarter-on-quarter to ₹106 crores.

  • Nutrition & Health segment achieved its highest EBITDA in 3 years at ₹36 crores, with margins improving to 15%.

  • Chemical Intermediates segment saw a strong rebound with revenue up 38% YoY and EBITDA up 240% YoY.

Concerns

  • Partial fulfillment of a large CDMO contract in Q1 FY27 due to raw material price escalations and a temporary pause requested by the innovator.

  • Lack of firm volume visibility for the large CDMO contract for coming quarters, though full protection is in place.

  • Pricing pressure in the pyridine business, particularly for commoditized variants, due to overcapacity in China.

  • Increased power, fuel, and logistics costs due to the Gulf crisis and higher volumes, though largely passed through.

Key financials

  1. Revenue ₹1,300 Cr +25%YoY
  2. EBITDA ₹209 Cr +36%YoY
  3. PAT ₹106 Cr +41%YoY

What they filed

Q1 FY27: revenue up 25.2%, net profit up 41.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue1,045 1,057 1,051 1,038 1,121 +7%1,051 −1%1,179 +12%1,300 +25%
EBITDA124 138 147 142 135 +9%126 −9%163 +11%199 +40%
Net profit59 69 74 75 69 +17%47 −32%86 +16%106 +41%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹1,300 Cr Total
  • Specialty Chemicals ₹533 Cr 41.0%
  • Chemical Intermediates ₹524 Cr 40.3%
  • Nutrition & Health ₹243 Cr 18.7%

Capital allocation

medium confidence
  • M&A Remidex Pharma Acquisition · Integrated

    Strengthened presence with Tier 1 customers in India for premixes business.

    On the M&A front, we successfully completed the integration of Remidex Pharma, and we are witnessing encouraging traction from Tier 1 human nutrition customers.

Guidance & targets

Capacity

  • New Multipurpose Plant Commissioning Capacity · end of current calendar year · High confidence Commissioned
    In the new multipurpose plant remains on track for commissioning by the end of current calendar year, further strengthening of our CDMO and Fine Chemicals growth road map.

    — Shyam Bhartia

EBITDA

  • Full Year EBITDA EBITDA · FY27 · High confidence ₹750-800 crores
    Regarding your first point, whether we want to upgrade our guidance, we would like to stick with the same guidance of INR750 crore to INR800 crore.

    — Varun Gupta

  • First Half EBITDA EBITDA · H1 FY27 · High confidence ₹400 crore plus
    EBITDA in the first half will be around INR400 crore plus.

    — Varun Gupta

Operational Efficiency

  • Lean Savings Operational Efficiency · FY27 · High confidence ₹100 crore
    On the operations and ESG front, we remain firmly on track, targeting INR100 crore of lean savings in FY27.

    — Deepak Jain

Capacity Utilization

  • Niacinamide Plant Capacity Utilization Capacity Utilization · end of this year · Medium confidence 70% plus
    we are hoping to take it up to 70% plus by end of this year.

    — Deepak Jain

Growth Drivers

  • Growth Leadership Growth Drivers · FY27 · High confidence Specialty Chemicals and Nutrition alongside a recovery in acetyls
    FY 2027, we expect growth to be led by Specialty Chemicals and Nutrition alongside a recovery in acetyls.

    — Shyam Bhartia

Financial Performance

  • Sequential Revenue and EBITDA Financial Performance · coming quarters · Medium confidence Improvement
    We anticipate sequential improvement in revenue and EBITDA over the coming quarters.

    — Shyam Bhartia

What to watch in Q2 FY27

Large CDMO Contract Volume Visibility

Next month (for Q3 planning) / Next quarter
Current Partial volumes in Q1 FY27, no firm visibility for Q2/Q3
Target Clarity on full volume commitment for the large CDMO contract

Why it matters

This contract is a significant contributor, and full utilization impacts revenue and EBITDA.

As and when they have the visibility, they will provide us. Unfortunately, they have not given us a firm time line. But in order to plan for Q3, we will need some clarity from them within the next month or so.

Risks & concerns

  • CDMO Contract Volume Uncertainty

    medium

    Lack of firm volume visibility for a large CDMO contract for coming quarters due to innovator's internal scenarios and raw material price escalations, though full protection is in place.

    Management acknowledged

  • Acetyl Segment Volatility

    medium

    Inherent volatility in the Acetyl segment makes Q4 performance unpredictable, influencing conservative full-year guidance.

    Management acknowledged

  • Pyridine Pricing Pressure

    medium

    Overcapacity in China is causing acute pricing pressure in commoditized pyridine variants, though the company is mitigating this by focusing on higher-value derivatives.

    Management acknowledged

  • Raw Material & Energy Price Volatility

    medium

    Geopolitical events (Gulf crisis) led to increased LSHS/natural gas costs, impacting power and fuel expenses, and raw material price escalations affected CDMO contract execution. Management states these were largely passed through.

    Management acknowledged

Q&A highlights

6 direct
CDMO contract contribution and future volume visibility Partial
We did not serve the full volumes last quarter as the innovator had confirmed because in between the raw material prices had escalated due to war and the innovator asked us to take a temporary pause till pricing came down... They have not finalized and hence, I cannot provide any further visibility. But in the unforeseen circumstances of they not giving us any volume, we have full protection.

Reveals that a key CDMO contract was not fully utilized in Q1 due to external factors (raw material prices, innovator request) and future volume visibility remains uncertain, though the company has contractual protection.

Asked by Siddharth Gadekar

CDMO funnel peak revenue potential Direct
we explained 5 new molecules which we have added. Most of them come from pharma or personal care segment and are early stage. And hence, right now, it is difficult to comment on the peak potential of those new molecules. And hence, we have not updated that INR1,500 crore number.

Clarifies that while the number of confirmed molecules in the CDMO pipeline has increased, the overall peak revenue potential figure hasn't been updated because the new additions are in early stages, implying a longer gestation period for their full impact.

Asked by Siddharth Gadekar

Full year EBITDA guidance upgrade Partial
we would like to stick with the same guidance of INR750 crore to INR800 crore... But given the volatility which exists in the market, particularly on the Acetyl segment, we never know what happens in Q4. right? So the fundamentals are strong, which make us believe that sequentially will improve. But obviously, there is always a risk if the market go down again in Q3, Q4.

Management maintains its full-year EBITDA guidance despite a strong Q1, citing market volatility, especially in the Acetyl segment, as a reason for caution, even while expressing optimism for sequential improvement.

Asked by Abhijit Akella

Specialty Chemical segment sequential growth and CDMO contract impact Direct
Q4 is always a heavy quarter for us because of the year-end... So from Q4 to Q1, sequential trajectory is not the factor of what is happening in the business... we have not served the full volume in Q1 because customers asked us to delay some of that to Q2 because of the price escalations on raw material side.

Explains that sequential comparisons from Q4 to Q1 are affected by seasonality and the partial fulfillment of the large CDMO contract due to raw material price escalations, providing context for the segment's performance.

Asked by Nitesh Dhoot

Dynamic nature of confirmed molecule count vs advanced stage bucket in CDMO pipeline Direct
molecules at advanced stage are not the same molecules which were 3 months back because some of them have moved to confirmed part of the pipeline and some from rest of the pipeline had moved to the advanced stage pipeline... So the whole funnel is moving... I just came back from U.S. last week, met 7 customers. On the back of that itself, there are at least 10 new opportunities we have now.

Clarifies that the CDMO pipeline is highly dynamic, with continuous movement of molecules between stages and constant addition of new opportunities, which explains why the 'advanced stage' count might appear static despite overall pipeline growth.

Asked by Nitesh Dhoot

Nutrition segment inventory benefits, pricing sustainability, and Niacinamide plant utilization Direct
we were very careful in building up the stock of high raw material inventory... the prices of finished goods, while they came down from the peak a little bit, they did not come down as much. And particularly in our specialty CDMO segment and Nutrition segment, we have been able to keep the pricing where they were in Q1... because the war restarted, the finished good prices have started to move up again in certain segments... [Niacinamide plant] at a 50% of that run rate, and we are hoping to take it up to 70% plus by end of this year.

Addresses concerns about inventory benefits fading, explaining that careful management, sustained pricing in specialty segments, and rising prices due to geopolitical events mitigated risks. Also provides an update on the Niacinamide plant's current and target utilization.

Asked by Nitesh Dhoot

Pricing dynamics of base pyridines and pyridine derivatives Direct
The pricing depends on which derivative you are talking about in Pyridine... There are some commoditized variants of Pyridine... The pricing pressure is more acute there because of the overcapacity in China. But because increasingly, our focus is more on either pyridine downstream, more advanced derivatives or the picoline part of it, where the pricing is holding up.

Details the nuanced pricing environment within the pyridine portfolio, highlighting pressure on commoditized base variants due to China's overcapacity, but stable pricing for higher-value, advanced derivatives, which is the company's strategic focus.

Asked by Archit Joshi

Increase in power, fuel, and logistics expenses Direct
the power and fuel expenses have gone up on account of two reasons. One, first reason is year-on-year, our volumes have increased and so has the quantity of power and fuel. Second, because of this Gulf crisis, the cost of LSHS or the natural gas has also gone up... bulk of the increase is due to the logistic cost where we have been hit by the increase in the cost of logistics... which we were able to successfully pass on to our customers as is reflected in our increase in pricing.

Explains that increased power, fuel, and logistics costs were driven by higher volumes and external factors like the Gulf crisis, but reassures that these cost increases were largely passed through to customers, mitigating margin impact.

Asked by Harsh Shah

2 min read 6 chapters

Detailed narrative

Strong Q1 FY27 Financial Performance

Jubilant Ingrevia Limited reported a robust start to FY27, with revenue reaching a 15-quarter high of ₹1,300 crores, marking a 25% year-on-year growth. EBITDA increased significantly by 36% year-on-year and 22% sequentially to ₹209 crores. Net Profit After Tax (PAT) also saw strong growth, rising 41% year-on-year and 22% quarter-on-quarter to ₹106 crores, reflecting healthy volume growth and improved realizations across its diverse business segments.

Segmental Growth and Margin Expansion

The Specialty Chemicals business delivered ₹533 crores in revenue, growing 11% year-on-year, with an EBITDA margin of 26%. The Nutrition & Health segment recorded ₹243 crores in revenue, up 36% year-on-year, achieving its highest EBITDA in three years at ₹36 crores, with margins improving to 15%. The Chemical Intermediates segment demonstrated a strong rebound, with revenue increasing 38% year-on-year to ₹524 crores and EBITDA surging 240% year-on-year to ₹57 crores, driven by robust demand and effective cost pass-throughs.

CDMO and Fine Chemicals Pipeline Momentum

The company's CDMO business continues to gain momentum, benefiting from the rollout of big innovator CDMO volumes in the agro segment and a threefold expansion in the pharma pipeline. The combined CDMO and Fine Chemicals pipeline now comprises over 100 molecules with a peak revenue potential exceeding ₹3,500 crores, including 25 confirmed molecules. Five new molecules were added in Q1 FY27 across pharma, semiconductor, and personal care segments.

Strategic Capacity Expansion and Operational Efficiency

Jubilant Ingrevia is on track to commission its new multipurpose plant by the end of the current calendar year, which is expected to strengthen its CDMO and Fine Chemicals growth roadmap. The new Niacinamide plant, with an annual capacity of 5,000 tons, is currently operating at a 50% run rate, with a target to reach over 70% utilization by the end of the calendar year. The company is also targeting ₹100 crores in lean savings for FY27 and advancing its Supernova program with new Gen AI use cases.

Navigating Contractual and Market Volatility

The company faced challenges with a large CDMO contract, which did not see full volume fulfillment in Q1 FY27 due to raw material price escalations and a temporary pause requested by the innovator. While future volume visibility for this contract remains uncertain, management confirmed full contractual protection. The pyridine business experienced pricing pressure in commoditized variants due to overcapacity in China, but the company's focus on higher-value derivatives helped mitigate this impact.

Cost Management Amidst External Pressures

Increased power, fuel, and logistics expenses were noted during the quarter, attributed to higher volumes, the Gulf crisis impacting LSHS and natural gas costs, and general logistics inflation. However, management successfully passed through these increased costs to customers, as reflected in improved realizations. This agile operational strategy helped maintain healthy margins despite external cost pressures.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls